You just read:

Betagenon/Baltic Bio Announces Positive Results From a 28-day Phase IIa Trial of the First-in-class AMPK Activator O304 in Type 2 Diabetics

News provided by

Betagenon AB

02 Nov, 2017, 10:21 GMT